GlaxoSmithKline PLC Profile



Odds of Distress

Analyze Filter    Fiscal Quarter End: December 31, 2019
Equity ratings for GlaxoSmithKline PLC are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting September 6, 2019 and ending today December 5, 2019. Click here to learn more.

GlaxoSmithKline PLC Profile

Next fiscal quarter end is expected on December 31, 2019. GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 95490 people. more
GlaxoSmithKline PLC Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
GlaxoSmithKline PLC SEC Filings
GlaxoSmithKline PLC SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameGlaxoSmithKline PLC
CEOEmma WalmsleyView All
Thematic Classification
Currently Active Investing Idea
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Bond Rating
Healthcare, Drug Manufacturers - General
InstrumentUSA Stock View All
LocationUnited Kingdom
Business Address980 Great West Road
Foreign Associate  UK
ExchangeBATS Exchange
CIK Number0001131399
IndustryDrug Manufacturers?General
Phone44 20 8047 5000
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterSeptember 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestNovember 15, 2019
GlaxoSmithKline PLC (GSK) is traded on BATS Exchange in USA. It is located in 980 Great West Road and employs 95,490 people. GlaxoSmithKline PLC is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with total capitalization of 104.19 B. GlaxoSmithKline PLC runs under Healthcare sector within Drug Manufacturers?General industry. The entity has 2.49 B outstanding shares of which 7.55 M shares are currently shorted by investors with about 2.29 days to cover shorted positions. GLAXOSMITHKLINE P has about 5.12 B in cash with (5.78 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.08.
Check GlaxoSmithKline PLC Probability Of Bankruptcy

Ownership Allocation (%)

GlaxoSmithKline PLC Target Price Odds Analysis

Odds Below 45.07HorizonTargetOdds Above 45.07
91.17%30 days 45.07 8.70%
Based on normal probability distribution, the odds of GlaxoSmithKline PLC to move above current price in 30 days from now is about 8.7 (This GlaxoSmithKline PLC probability density function shows the probability of GlaxoSmithKline PLC Stock to fall within a particular range of prices over 30 days) .

GlaxoSmithKline PLC Top Holders

GlaxoSmithKline PLC Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

GlaxoSmithKline PLC Key Fundamentals

GlaxoSmithKline PLC Against Markets

Did you try this?

Run Theme Ratings Now


Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

GlaxoSmithKline PLC Upcoming and Recent Events

GlaxoSmithKline PLC Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportFebruary 5, 2020
Next Earnings ReportMay 6, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndFebruary 5, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

GlaxoSmithKline PLC Corporate Filings

GlaxoSmithKline PLC SEC Reporting

Unclassified Corporate Event

GlaxoSmithKline PLC Distributions to stockholders

GlaxoSmithKline PLC Corporate Directors

Vindi Banga Senior Independent Non-Executive Director
Lynn Elsenhans Independent Non-Executive Director
Daniel Podolsky Non-Executive Independent Director
Please also check Risk vs Return Analysis. Please also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.